Sarcosine

Sarcosine at a Glance

Sarcosine is glycine with a methyl group attached — N-methylglycine, a natural intermediate in the body’s methylation and glycine metabolism. It is a minor metabolite by any ordinary measure, and would be of no interest at all except for one specific pharmacological property: it blocks the transporter that clears glycine out of the synapse.

That matters because of what glycine does at the NMDA receptor. NMDA receptors need two things to open — glutamate at the main site, and glycine (or D-serine) at a separate co-agonist site. If the co-agonist site is not occupied, glutamate alone does nothing. Sarcosine inhibits GlyT-1, the transporter that pulls glycine back out of the synaptic cleft, so glycine accumulates and NMDA signalling is enhanced.

This is a targeted intervention aimed at a specific theory: the NMDA-hypofunction model of schizophrenia, which holds that under-active glutamate signalling drives the negative and cognitive symptoms that antipsychotics handle poorly. Sarcosine is one of the more credible tests of that idea, and it has produced some of the better results in a field with a long record of disappointment.

It should be said plainly that this is where the evidence sits. Sarcosine is also marketed as a general mood and cognition nootropic, but that use borrows its credibility from trials in people with a serious psychiatric illness. Enhancing NMDA signalling in a healthy brain is not the same intervention as correcting a hypothesised deficit in an ill one.

What It’s Used For

• Schizophrenia, as an adjunct to antipsychotics — the use with real support. Sarcosine outperformed both placebo and D-serine on symptom, negative-symptom, quality-of-life and functioning measures when added to antipsychotics ^{2Reference 2Lane HY et al. · 2005RCTSarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trialView study →}, and a 2020 meta-analysis of double-blind randomised trials put the effect on overall symptoms at SMD ≈ 0.51 ^{5Reference 5Chang CH et al. · 2020Meta-analysisEfficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials — meta-analysisView study →}.
• Negative symptoms specifically — the domain antipsychotics handle worst, and where sarcosine looks most convincing ^{2Reference 2Lane HY et al. · 2005RCTSarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trialView study →}.
• Schizophrenia monotherapy — a randomised, double-blind trial found 2 g/day produced greater symptom improvement particularly in antipsychotic-naïve patients, though with no overall between-group significance ^{4Reference 4Lane HY et al. · 2008RCTSarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study — randomised controlled trialView study →}.
• Depression — a single 40-patient citalopram-controlled RCT, unreplicated ^{7Reference 7Huang CC et al. · 2013RCTInhibition of glycine transporter-I as a novel mechanism for the treatment of depression — randomised controlled trialView study →}.
• Cognition in schizophrenia — the claim most often overstated: the 2020 meta-analysis found no standalone cognitive effect, and the one positive signal required co-administering sodium benzoate ^{5,8Reference 5Chang CH et al. · 2020Meta-analysisEfficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials — meta-analysisView study →Reference 8Lin CY et al. · 2017RCTAdjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial — randomised controlled trialView study →}.
• Obsessive-compulsive disorder — one small open-label study, no placebo control ^{9Reference 9Wu PL et al. · 2011Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study — open-label trialView study →}.
• General nootropic use — extrapolation. Claims that sarcosine reliably improves mood or cognition in healthy, non-clinical users were not backed by a citable trial in this pass.

The important framing: this is a clinical adjunct, not a casual supplement. People with, or at risk of, psychiatric illness should not self-treat, and the trials that support sarcosine were all run alongside proper psychiatric care rather than instead of it.

How It Works

The NMDA receptor is unusual in requiring two different molecules to open. Glutamate binds the primary site; glycine or D-serine must simultaneously occupy a separate co-agonist site on a different subunit. This dual requirement is a safety interlock — it means glutamate alone cannot excite a neuron, which matters given how damaging unchecked NMDA activation is.

Glycine concentration at the synapse is controlled by GlyT-1, a transporter on surrounding glial cells that continuously pumps glycine out of the cleft and keeps the co-agonist site only partially saturated. That partial saturation is the lever. Inhibit GlyT-1, glycine lingers, more receptors have their co-agonist site filled, and NMDA signalling increases — without adding any glutamate, and therefore without the excitotoxic risk of stimulating the primary site directly.

Sarcosine is that inhibitor. It is a weak, competitive GlyT-1 blocker, which is why doses are measured in grams rather than milligrams, and it is also a substrate for the transporter itself.

Why aim at NMDA in schizophrenia at all? Because drugs that block NMDA receptors — ketamine, PCP — reproduce not just the positive symptoms of psychosis but the negative and cognitive ones too, which dopamine-based models never explained well. That observation generated the NMDA-hypofunction hypothesis, and enhancing co-agonist-site occupancy is its most direct pharmacological test. Sarcosine has performed better in that test than D-serine, which supplies the co-agonist directly but did not separate from placebo in a head-to-head trial ^{2Reference 2Lane HY et al. · 2005RCTSarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trialView study →} — a hint that raising synaptic glycine locally works better than flooding the system.

Pharmacology & Research

Sarcosine (N-methylglycine) is not a nutrient and has no deficiency state — it is a small-molecule drug that happens to be endogenous, and essentially all of its evidence comes from psychiatry. Its single relevant property is inhibition of the type-1 glycine transporter (GlyT-1), which raises glycine at the NMDA-receptor co-agonist site and enhances NMDA signalling. That places it inside one specific research programme — the NMDA-hypofunction model of schizophrenia — where it is one of the better-performing tests of the idea, with several small randomised trials and two meta-analyses behind it. Everything outside that programme (depression, OCD, and especially “nootropic” use in healthy people) is thinner, and the whole literature has a structural weakness: most of the positive trials come from a small number of Taiwanese research groups. Doses are measured in grams because sarcosine is a weak, competitive blocker, and its benefit has only ever been demonstrated in diagnosed patients under psychiatric care.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume, then tempered for consistency and for how much the effect depends on treating a diagnosed illness rather than a healthy user. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

01Schizophrenia symptoms (adjunct)Promising78%Multiple double-blind RCTs + 2 meta-analyses; add-on to non-clozapine antipsychotics; few research groups

02Negative symptomsPromising71%The most consistent symptom domain across the same RCTs; still small, same-group caveat

03Schizophrenia monotherapyPromising47%One RCT; effect concentrated in antipsychotic-naïve subgroup, no overall between-group significance

04DepressionShaky43%One 40-patient citalopram-controlled RCT + rodent models; unreplicated

05Cognition in schizophreniaShaky34%Meta-analysis found no cognitive effect; a benzoate co-treatment RCT is the lone positive signal

06Obsessive-compulsive disorderShaky27%Single open-label study, no placebo, ~20% mean symptom reduction

Mechanisms

Pharmacokinetics

Sarcosine is dosed in grams (1–2 g/day) precisely because it is a weak, competitive GlyT-1 blocker rather than a high-affinity drug, and because it is itself a substrate for the transporter it inhibits. It is an endogenous metabolite of choline breakdown and the glycine–betaine methylation cycle, so baseline levels are non-zero and there is no deficiency state to correct. Detailed human absorption, half-life and food-effect data specific to supplemental sarcosine are not well characterised in the public literature — the trials report dosing and outcomes, not formal pharmacokinetics. Central effect is presumed to reflect raised synaptic glycine rather than a direct receptor action. Trial durations were six to twelve weeks; longer-term kinetics and steady-state behaviour are uncharacterised.

Clinical trials

Registered activity is concentrated in schizophrenia, with smaller efforts in depression, OCD and Parkinson’s-disease dementia; most listings trace back to the same Taiwanese investigators, and there is little industry-sponsored large-scale trial activity for this off-patent molecule.

Last checked: August 2026.

Dietary Sources

Sarcosine is an endogenous metabolite, not a dietary essential — the body makes it during choline breakdown and in the glycine–betaine methylation cycle — so there is no requirement, no deficiency state, and no recommended intake. It occurs in trace amounts in ordinary foods and is a normal component of muscle tissue.

Food	Sarcosine content	Notes
Egg yolk	Trace	Endogenous animal-tissue metabolite
Meat (incl. turkey)	Trace	Present in muscle tissue
Legumes	Trace	Small amounts

The quantities in food are negligible — milligram-scale at most — against the gram-level doses used in research, so no realistic diet supplies a “sarcosine dose.” One point worth flagging because it surfaces in garbled form in supplement marketing: sarcosine has been studied as a urinary biomarker in prostate cancer research. Being measurable in a disease is not the same as causing or treating it, and the biomarker literature says nothing about supplementation.

Intake & Dosage

These are doses studied in research, not a personal recommendation.

• Studied range: roughly 1–2 g/day, with 2 g/day the dose used in nearly all schizophrenia trials ^{1,2,4Reference 1Tsai G et al. · 2004RCTGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia — randomised controlled trialView study →Reference 2Lane HY et al. · 2005RCTSarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trialView study →Reference 4Lane HY et al. · 2008RCTSarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study — randomised controlled trialView study →}. The OCD open-label study used a flexible 0.5–2 g/day schedule ^{9Reference 9Wu PL et al. · 2011Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study — open-label trialView study →}.
• No RDA/AI or UL exists — sarcosine is not a nutrient. The absence of an established upper limit does not mean high doses are safe; it means no authority has evaluated it.
• Duration: trials ran six to twelve weeks. Longer-term dosing is uncharacterised.
• Context: every efficacy trial was run within psychiatric care — as an adjunct to antipsychotics, or as monotherapy in drug-naïve patients under supervision. Neither is a self-directed protocol. The most important dosing note is not a number: anyone considering sarcosine for a psychiatric indication should do so with a clinician, and stopping or replacing antipsychotic medication with a supplement is dangerous.

Safety

The molecule itself looks benign in trials: adverse-event rates did not distinguish sarcosine from placebo, and reported complaints were mild and gastrointestinal ^{1,2,5Reference 1Tsai G et al. · 2004RCTGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia — randomised controlled trialView study →Reference 2Lane HY et al. · 2005RCTSarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trialView study →Reference 5Chang CH et al. · 2020Meta-analysisEfficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials — meta-analysisView study →}. The real risk here is contextual — what sarcosine is used for and by whom.

Safety at a Glance

✅ Low / no toxicityDrug interactions

• Good safety profile in the cited trials. Adverse-event rates did not distinguish sarcosine from placebo; complaints were mild and gastrointestinal ^{1,2,5Reference 1Tsai G et al. · 2004RCTGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia — randomised controlled trialView study →Reference 2Lane HY et al. · 2005RCTSarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trialView study →Reference 5Chang CH et al. · 2020Meta-analysisEfficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials — meta-analysisView study →}.
• A clinical adjunct, not a general nootropic. Its evidence comes from a serious psychiatric illness treated under supervision; over-the-counter mood/focus marketing extrapolates well beyond the data.
• Do not self-treat psychiatric symptoms. Sarcosine has never been tested as a replacement for prescribed treatment, and stopping antipsychotics is dangerous.
• The clozapine caveat. Sarcosine added no benefit over placebo when combined with clozapine ^{3Reference 3Lane HY et al. · 2006RCTGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia — randomised controlled trialView study →} — the effect is regimen-dependent, not universal.
• NMDA signalling in a healthy brain is not obviously benign — that use is untested.
• Interactions and pregnancy/lactation not formally assessed in this pass.

Full Safety & Interactions Detail

Sarcosine showed a good safety profile in the cited trials, with adverse-event rates that did not distinguish it from placebo, and its toxicity appears low ^{1,2,5Reference 1Tsai G et al. · 2004RCTGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia — randomised controlled trialView study →Reference 2Lane HY et al. · 2005RCTSarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trialView study →Reference 5Chang CH et al. · 2020Meta-analysisEfficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials — meta-analysisView study →}. Reported complaints are mild and gastrointestinal. The real risk here is contextual.

• The framing matters more than the pharmacology. Sarcosine is a clinical adjunct studied in schizophrenia, not a casual over-the-counter mood booster. The trials were conducted alongside psychiatric care, with monitoring, in diagnosed patients — that is the context in which the benefit was observed.
• The clozapine null. Unlike other antipsychotics, sarcosine added no benefit over placebo when combined with clozapine ^{3Reference 3Lane HY et al. · 2006RCTGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia — randomised controlled trialView study →}, a reminder the effect is regimen-dependent rather than universal.
• Who should be cautious: anyone with a psychiatric diagnosis or family history, anyone taking psychiatric medication, and anyone considering it as a replacement for prescribed treatment — which it is not and has never been tested as.

Scope disclosure (honesty, not a claim): interactions were not formally assessed — no dedicated drug-interaction studies exist. On mechanistic grounds the interactions that would warrant attention are with other NMDA-active or glycine-site agents (D-serine, glycine, D-cycloserine, memantine, ketamine) and with antipsychotics, where the effect is both the point (add-on benefit) and the caveat (no benefit with clozapine). Pregnancy/lactation were not assessed (see below). No Upper Limit has been set — do not read the absence of a limit as licence for unlimited intake. Never imply safety from an absence of reports.

Pregnancy & Lactation

? Not established in pregnancy? Not established in lactation

Not assessed. No human data exist for supplemental sarcosine in pregnancy or lactation. NMDA signalling has an established role in neurodevelopment, so a drug deliberately designed to enhance it is not a reasonable unstudied exposure during pregnancy. Pregnant or breastfeeding people should not use it without discussing it with a qualified practitioner.

Related compounds

• Glycine — the parent amino acid sarcosine is derived from and whose synaptic concentration it raises.
• D-serine — the other main NMDA co-agonist-site agent; it underperformed sarcosine head-to-head, failing to separate from placebo where sarcosine did ^{2Reference 2Lane HY et al. · 2005RCTSarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trialView study →}.
• Sodium benzoate — a D-amino-acid-oxidase inhibitor studied in combination with sarcosine, where the pair improved cognition though sarcosine alone did not ^{8Reference 8Lin CY et al. · 2017RCTAdjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial — randomised controlled trialView study →}.

References

1. Tsai G, Lane HY, Yang P, Chong MY, Lange N. (2004). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia — randomised controlled trial. Biol Psychiatry. https://pubmed.ncbi.nlm.nih.gov/15023571/
2. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study — randomised controlled trial. Arch Gen Psychiatry. https://pubmed.ncbi.nlm.nih.gov/16275807/
3. Lane HY, Huang CL, Wu PL, et al. (2006). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia — randomised controlled trial. Biol Psychiatry. https://pubmed.ncbi.nlm.nih.gov/16780811/
4. Lane HY, Liu YC, Huang CL, et al. (2008). Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study — randomised controlled trial. Biol Psychiatry. https://pubmed.ncbi.nlm.nih.gov/17659263/
5. Chang CH, Lin CH, Liu CY, et al. (2020). Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials — meta-analysis. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/32122256/
6. Goh KK, Wu TH, Chen CH, Lu ML. (2021). Efficacy of NMDA receptor modulator augmentation in schizophrenia: a meta-analysis of randomised controlled trials — meta-analysis. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/33406959/
7. Huang CC, Wei IH, Huang CL, et al. (2013). Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression — randomised controlled trial. Biol Psychiatry. https://pubmed.ncbi.nlm.nih.gov/23562005/
8. Lin CY, Liang SY, Chang YC, et al. (2017). Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial — randomised controlled trial. World J Biol Psychiatry. https://pubmed.ncbi.nlm.nih.gov/26691576/
9. Wu PL, Tang HS, Lane HY, Tsai CA, Tsai GE. (2011). Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study — open-label trial. J Clin Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/21508860/
10. Marchi M, Galli G, Magarini FM, et al. (2021). Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials — systematic review. Expert Opin Drug Metab Toxicol. https://pubmed.ncbi.nlm.nih.gov/33538213/

View all 10 references▾